Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2623696 | 0.90 | TLR7 (0.47) | TLR7CYP3A4CYP1A2CYP2C8CYP2C9 | |
| SCHEMBL2432179 | 0.87 | CYP4F2 (0.56) | TLR7CYP4F2CYP4A11 | |
| SCHEMBL4454899 | 0.86 | PPARA (0.58) | TLR7PPARGPPARACYP3A4CYP1A2 | |
| SCHEMBL15839483 | 0.84 | PPARA (0.56) | TLR7PPARGPPARACYP3A4CYP1A2 | |
| SCHEMBL10835928 | 0.83 | CYP4F2 (0.47) | TLR7PPARACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4332327 | 0.83 | CYP4F2 (0.52) | TLR7CYP4F2CYP4A11 | |
| SCHEMBL14122353 | 0.82 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL2623700 | 0.82 | ALDH1A1 (0.57) | CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL26239818 | 0.82 | CYP4F2 (0.55) | PPARGPPARACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4458645 | 0.81 | CYP3A4 (0.50) | TLR7PPARGPPARACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-8772226-B2 | Methods and compositions for the detection of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-7482484-B2 | Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | NR1H3, LDLR, NR1H2 | TLR7 287/4885PPARG 309/4885PPARA 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.